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Abstract: Endothelin receptor antagonism has emerged as an important therapeutic approach 
in pulmonary arterial hypertension (PAH). Bench to bedside scientiﬁ  c research has clearly 
shown that endothelin-1 (ET-1) is over-expressed in several forms of pulmonary vascular 
disease and plays an important pathogenetic role in the development and progression of PAH. 
Oral endothelin receptor antagonists (ERAs) have been shown to improve exercise capacity, 
functional status, pulmonary hemodynamics, and delay the time to clinical worsening in several 
randomized placebo-controlled trials. Bosentan, the ﬁ  rst oral ERA, was approved in 2001 and 
since that time it has established a strong record of safety and efﬁ  cacy in PAH. More recently, 
two additional ERAs, ambrisentan and sitaxsentan, have been approved for use. The objective 
of this review is to evaluate the available evidence supporting the efﬁ  cacy, pharmacology, safety 
and tolerability, and patient-focused perspectives for bosentan, the ﬁ  rst approved ERA for PAH. 
Ongoing and forthcoming randomized trials are also highlighted including the application of 
bosentan in combination with other PAH therapies.
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Introduction
Pulmonary arterial hypertension (PAH) is a progressive arteriopathy characterized by 
vasoconstriction, pulmonary vascular remodeling, and in situ thrombosis. Until the 
mid-1980s, the prognosis for individuals diagnosed with PAH was dismal with a median 
survival of less than 3 years from the time of diagnosis.1 The introduction of therapies 
targeting the dysregulated pulmonary vasculature, including parenteral, inhaled and oral 
medications, has dramatically improved PAH survival. Since the discovery of ET-1 in 
the late 1980s, scientiﬁ  c research has established that excess synthesis of ET-1 is an 
important factor in the pathogenesis of PAH.2 A potent vasoconstrictor and mitogen, 
endothelin-1 (ET-1) plays a central role in the highly regulated cross-talk between the 
vascular smooth muscle and endothelium. This led to the development of a class of 
drugs called endothelin receptor antagonists (ERAs). In 1994 Clozel and colleagues 
reported the discovery of a dual endothelial receptor antagonist.3 Bosentan (Tracleer®; 
Actelion Pharmaceuticals Ltd, Allschwil, Switzerland) was approved for use in 2001, 
making it the ﬁ  rst FDA-approved oral therapy for PAH.
On the basis of a series of randomized controlled clinical trials, bosentan, ambris-
entan, and sitaxsentan are the ERAs licensed in the United States and/or Europe as 
monotherapy for patients with Group 1 World Health Organization pulmonary arterial 
hypertension (Table 1). This class of drug offers not only improved symptom control, 
but also the prospect of improved quality of life. In this review we aim to discuss the 
pharmacology, therapeutic beneﬁ  ts and safety proﬁ  le of bosentan in patients with PAH. 
Bosentan is the ﬁ  rst ERA to be approved for the treatment of PAH patients who are Drug Design, Development and Therapy 2009:3 112
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New York Heart Association (NYHA) Class III and IV (for 
NYHA functional class deﬁ  nition, see Table 2). Ambrisentan 
and sitaxsentan are approved for PAH patients with NYHA 
Class II–IV in the US (ambrisentan) and in Europe, Australia 
and Canada (sitaxsentan).
ET -1: mediator of pulmonary 
vascular tone and growth
Endothelial cells synthesize and release pre-pro-endothelin, 
which is subsequently cleaved by endothelin converting 
enzyme to produce the 22 amino acid vasoactive peptide 
ET-1. ET-1 is a potent vasoconstrictor and early investigations 
focused on defining its role in the homeostasis of the 
systemic and pulmonary vasculature. Identiﬁ  cation of ET-1 
over-expression in the plasma and the lungs of patients with 
PAH provided evidence that it was important in the patho-
genesis of human pulmonary hypertension.4 More recent 
data have demonstrated that ET-1, in addition to its potent 
vasomotor activity, regulates extracellular matrix formation 
and mitogenesis via endocrine and paracrine mechanisms. 
Dysregulation of ET-1 signaling can mediate to abnormal 
growth and apoptosis of endothelial cells, smooth muscle 
cells, ﬁ  broblasts, and pericytes.5,6 This property makes it a 
potential node of control in both the vasoconstrictive and 
proliferative components of PAH pathogenesis.7–9 Its integral 
role in these processes made ET-1 signaling a therapeutic 
target for PAH.
ET -1 receptor biology
ET-1 acts on two G protein-coupled receptors referred to as 
the endothelin A (ETA) and endothelin B (ETB) receptors.10,11 
ETA receptors are abundant on vascular smooth muscle, 
pericytes, and ﬁ  broblasts. Their activation by ET-1 results 
in vasoconstriction and proliferation in vitro.12 ETB receptors 
are abundant on both endothelial cells and vascular smooth 
muscle, particularly in the distal lung microvasculature.13 
When bound by ET-1 ligand, ETB receptor response is 
varied, depending upon the cell type on which the receptor is 
expressed. In the presence of ET-1, endothelial ETB trigger the 
release of vasodilators and antiproliferative molecules such as 
prostacyclin and nitric oxide.14 In addition, endothelial ETB 
clears ET-1 from the circulation.15,16 However, when expressed 
on vascular smooth muscle cells, ETB receptors mediate ET-1 
induced vasoconstriction and are pro-proliferative, much like 
the ETA receptor.
Pharmacology and pharmacokinetics 
of bosentan
ERAs are orally administered direct inhibitors of ET-1 
receptors. Bosentan acts nonselectively on both the ETA and 
ETB receptors (ETA: ETB 20:1), whereas both sitaxsentan (ETA: 
ETB 6500:1) and ambrisentan (ETA: ETB 260:1) are signiﬁ  cantly 
more selective for the ETA receptor. Bosentan’s pharmacokinet-
ics are dose-proportional up to 600 mg (single dose) and 500 mg 
(multiple doses) daily. It is dosed 62.5 mg twice a day the ﬁ  rst 
4 weeks and 125 mg twice a day thereafter. No dose adjustment 
is required in adults based on sex, age, bodyweight or mild 
hepatic impairment.17,18 Following oral administration, bosentan 
reaches peak plasma concentrations after about 3 hours, and it 
reaches steady state conditions after 3 to 5 days.
Bosentan’s bioavailability is about 50%, and is similar 
for either a single 125 mg tablet or two 62.5 mg tablets. 
Concomitant intake of food does not have a signiﬁ  cant impact 
on absorption.19
Distribution, metabolism 
and elimination
Bosentan is highly protein-bound, with approximately 
98% bound to albumin. It is metabolized by the hepatic 
cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9.18 
Three metabolites are formed, one of which, Ro 48–5033, is 
biologically active, and may contribute to up to 20% of the 
parent compound’s action. The elimination of unchanged 
bosentan and its metabolites is primarily through the biliary 
system, with less than 3% excreted renally.18 The half-life 
of bosentan is 5 to 8 hours.20 Due to its interaction with the 
cytochrome P450 enzymes, bosentan should be avoided in 
patients with moderate to severe liver disease or baseline 
liver transaminases greater than 3 times the upper limit of 
normal (see Safety and tolerability).
Table 1 World Health Organization (WHO) classiﬁ  cation of 
pulmonary hypertension58
WHO Group 1. Pulmonary arterial hypertension
•  Idiopathic PAH (IPAH)
• Familial  PAH
• Related  to:
  Connective  tissue  diseases
  HIV
  Portal  hypertension
  Anorexigens
  Congenital  heart  diseases
•  Primary pulmonary hypertension of the newborn
•  PAH with venule/capillary involvement (pulmonary veno-occlusive disease)
•  Hemoglobinopathies, glycogen storage disorders, Gaucher’s
•  Hereditary hemorrhagic telangectasia (Osler-Weber-Rendu)Drug Design, Development and Therapy 2009:3 113
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Drug interactions
Bosentan induces members of the cytochrome P450 family. 
Administration of bosentan therefore leads to increased 
metabolism of warfarin, and cyclosporin A, and HMG CoA 
reductase inhibitors.21,22 Combined use of these medications 
must be carefully considered, as clearance can be increased 
by up to 50%, necessitating dose adjustments in order to 
maintain therapeutic efﬁ  cacy. Concomitant administration 
of bosentan and inhibitors of CYP3A4, such as the azole 
fungicides, can increase the peak plasma concentration of 
bosentan by more than 2-fold. Lastly, use of bosentan and 
the oral hypoglycemic glyburide is contraindicated due a 
higher incidence of hepatoxicity and reduced plasma levels 
of both drugs.
Two additional interactions deserve special attention 
in the PAH patient. First is the interaction with phospho-
diesterase 5 (PDE5) inhibitors. Treatment with bosentan 
62.5 mg twice daily was associated with a two-fold increase 
in sildenaﬁ  l clearance. Increasing the dose of bosentan to 
125 mg twice daily led to a further increase in sildenaﬁ  l oral 
clearance, demonstrating that bosentan, in a dose dependant 
manner, decreases the plasma concentration of sildenaﬁ  l by as 
much as 55%.23,24 Similarly, in healthy volunteers, bosentan 
decreased tadalafil exposure by 41.5%.25 In addition, 
sildenaﬁ  l signiﬁ  cantly increases bosentan plasma levels.23 
The clinical implication of these pharmacologic interactions 
remains to be documented.
Second, bosentan decreases the effectiveness of hormonal 
oral contraceptives.26 Awareness of this effect is crucial for 
PAH patients, in whom pregnancy can induce a life-threatening 
pulmonary hypertensive crisis. Women of child-bearing 
age who are treated with bosentan must use two methods of 
contraception.
Practitioners prescribing bosentan must be aware of these 
potential drug-drug interactions, and make appropriate deci-
sions regarding coadministration.
Safety and tolerability
Bosentan is very well tolerated. The most common adverse 
effect is hepatotoxicity which results from the inhibition of 
a bile acid export pump by bosentan and its metabolites.27,28 
Elevation of liver function tests (aspartate aminotransferase 
– AST, alanine aminotransferase – ALT, and bilirubin) to 
greater than 3 times the upper limit of normal (ULN) can 
be seen in up to 10% of patients.29 Fortunately this effect is 
usually reversible and often improves with dose reduction, or 
discontinuation of therapy. In a post-market analysis of 4994 
patients on bosentan followed up prospectively for 30 months, 
the incidence of liver function tests above 3 times ULN was 
7.6%, with an annual rate of 10.1% and a discontinuation rate 
of  3.7%.30 As a result of the potential for liver toxicity, patients 
must have liver function assessed prior to starting bosentan, 
and monthly thereafter. In the event of AST and/or ALT ele-
vations to between 3 and 5 times ULN, dose reduction should 
be strongly considered. More severe elevations demand 
dose reduction, if not interruption/cessation of bosentan, 
especially when associated with elevations of bilirubin, or 
with symptoms such as right upper quadrant pain. Initiation 
of bosentan therapy is not recommended for individuals with 
baseline liver function tests greater than 3 times ULN. It is of 
note that, despite the potential for hepatotoxicity, bosentan 
has been used without major side effects in carefully selected 
patients with portopulmonary hypertension in the setting of 
mild hepatic failure.31
Other reported side effects are mild and include: leg 
edema (in up to 3%), mild decreases in hemoglobin, and nasal 
congestion. Fluid retention, typically reported as increased 
lower extremity edema and/or weight gain, can be seen in a 
minority of patients. In individuals with baseline ﬂ  uid reten-
tion and/or impaired left ventricular function, this side effect 
has the potential to be more clinically signiﬁ  cant, thus con-
sideration of alternative pulmonary hypertension therapies 
is reasonable for these patients. Hemoglobin reductions are 
Table 2 New York Heart Association (NYHA) functional classiﬁ  cation for pulmonary arterial hypertension
Class Description
I No signiﬁ  cant limitation of usual physical activity; ordinary physical activity does not cause increased dyspnea, fatigue, chest pain, 
or presyncope (asymptomatic)
II Moderate limitation of physical activity; no discomfort at rest, but normal physical activity causes mild symptoms (dyspnea, 
fatigue, chest pain, or presyncope)
III Marked limitation of physical activity; no discomfort at rest, but less than ordinary activity causes symptoms (dyspnea, fatigue, 
chest pain, or presyncope)
IV Dyspnea and/or fatigue at rest, symptoms are increased by almost any physical activity; inability to perform any physical activity; 
signs of right heart failure may be presentDrug Design, Development and Therapy 2009:3 114
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generally mild (mean reduction 0.9 gm/dL), more common 
at higher doses, and stabilize after 12 weeks. Hemoglobin 
should be assessed prior to initiation, monthly for the ﬁ  rst 
12 weeks and quarterly thereafter.
Clinical experience
with bosentan in PAH
Following favorable studies of safety and efﬁ  cacy in animal 
models of pulmonary hypertension, the ﬁ  rst pilot study of 
bosentan in humans was published in 2000.32 This study 
was designed to evaluate the dosing and safety of bosentan 
for patients with NYHA functional Class II, III, and IV 
PAH in two phases. The ﬁ  rst phase explored the safety, 
efﬁ  cacy and pharmacokinetics of parenteral bosentan in 
7 patients. This study showed that an infusion of high doses 
of intravenous bosentan (50–300 mg) acutely lowered both 
pulmonary and systemic vascular resistance. Following 
drug administration there was a transient increase in ET-1 
levels, consistent with the blockade of peptide clearance by 
endothelial ETB receptors. The second phase was designed 
to assess the functional and hemodynamic impact of oral 
bosentan (1000 mg twice daily) for 8 weeks. Unfortunately 
several of the patients died or suffered clinical deterioration 
during the second phase of the study necessitating early 
study termination.
In light of the promising hemodynamic ﬁ  ndings, these 
data led to the ﬁ  rst randomized, double-blind, placebo-
controlled trial to evaluate the clinical effects of bosentan 
as a long-term oral treatment for idiopathic PAH or PAH 
related to scleroderma.33 All patients were NYHA Class III 
at baseline, and the bosentan and placebo groups were well 
matched at baseline, with the exception of a slightly longer 
duration of disease before diagnosis in the placebo group. 
Over 12 weeks, oral bosentan (62.5 mg twice a day for 
4 weeks, then 125 mg twice daily) improved placebo-adjusted 
exercise capacity (6-minute walk distance, +76 meters; 
95% CI 12 to 39, p = 0.21), pulmonary vascular resistance 
(–415 dyn s cm-5, 95% CI –608 to –221, p  0.001), and 
NYHA Class. The incidence of hepatotoxicity (deﬁ  ned as 
an increase in liver function tests over 3 times upper limit of 
normal) in bosentan treated patients was 10% and resolved 
with discontinuation of the drug.
A second randomized trial designed as a 16-week, 
double-blind, placebo-controlled study, the Bosentan 
Randomized Trial of Endothelin Antagonist Therapy 
(BREATHE-1), showed that PAH patients treated with 
oral bosentan (62.5 mg twice a day for 4 weeks, then either 
125 mg or 250 mg twice daily) had improved exercise 
capacity as measured by the 6-minute walk distance, and 
functional class. In addition it delayed time to clinical 
worsening compared to placebo.29 Most patients were in 
NYHA Class III, with a few Class IV. In both groups, more 
patients had idiopathic PAH than PAH associated with 
connective tissue disorders. Subgroup analysis revealed that 
bosentan improved the walking distance from baseline in 
patients with idiopathic PAH (46-meter increase as opposed 
to a 5-meter decline in the placebo group) while bosentan 
only prevented deterioration in the walking distance among 
patients with PAH related to scleroderma. Abnormal hepatic 
function was found to be dose dependent. Increases of 
hepatic transaminases to more than 8 times the upper limit 
of normal was seen only in the bosentan groups: 3% in the 
group receiving 125 mg twice daily and 7% in the group 
receiving 250 mg twice daily. A substudy subsequently 
showed that bosentan improved right ventricular size and 
systolic function as well as left ventricular ﬁ  lling according 
to echocardiography.34 BREATHE-1 resulted in approval for 
the ﬁ  rst oral therapy for PAH.
A 1-year follow up, open label study evaluated the 
durability of clinical improvement in patients that were 
NYHA Class III at baseline.35 Six-minute walk distances, 
pulmonary hemodynamics and functional status were 
sustained for many patients. By 1 year, only 55% of patients 
were still in NYHA Class III, while 40% had improved 
to Class II. Only 4 of 29 patients required up titration to 
250 mg twice daily to maintain favorable clinical status. 
The incidence of hepatotoxicity was 9.7%, and no subject 
required drug discontinuation.
Two retrospective studies have assessed survival of 
PAH patients treated with bosentan.36,37 Two-year survival 
in both cohorts was similar (89% and 91%, respectively), 
and markedly improved compared with a survival rate of 
57% predicted by the equation formulated by the National 
Institutes of Health registry. Despite this encouraging data, 
the retrospective and uncontrolled nature of these bosentan 
data limit direct comparison to the earlier, prospective study. 
Of note, a second agent for PAH was required in only a 
minority of patients. In McLaughlin’s study 10% of the 
patients required concurrent epoprostenol therapy, and in 
Sitbon’s study 13% at 12 months (15% at 24 months) required 
additional therapy. Factors that predicted a worse outcome 
included NYHA Class IV and 6-minute walk distance below 
the median (358 meters) at baseline.36
The EARLY trial was a 6-month double blind, ran-
domized, placebo-controlled trial dedicated to PAH 
patients with mild symptomatic disease (NYHA Class II). Drug Design, Development and Therapy 2009:3 115
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Patients were enrolled if they were either treatment naïve or 
were on stable doses of sildenaﬁ  l monotherapy. Two primary 
endpoints, hemodynamic (mean change in pulmonary 
vascular resistance) and functional (change in 6-minute 
walk distance), were assessed. While there was a signiﬁ  cant 
reduction in pulmonary vascular resistance for patients on 
bosentan (placebo-adjusted, –22.6%, 95% CI –33.5 to –10.0, 
p  0.0001) the improvement in 6-minute walk distance was 
not signiﬁ  cant (19.1 meters, 95% CI 3.6 to 41.8, p = 0.07). 
These data suggest a possible beneﬁ  t of treating early PAH 
with bosentan.38
Three additional studies evaluated the efficacy of 
bosentan for patients with pulmonary hypertension associated 
with other clinical entities and age groups. For 19 pediatric 
patients with PAH related to congenital heart disease, 
BREATHE-3 showed improved pulmonary hemodynamics 
after a 12-week open-label trial of bosentan therapy (dosing 
was adjusted by weight).39 Approximately 50% of the patients 
in BREATHE-3 were on concomitant epoprostenol therapy. 
Two studies have evaluated the use of bosentan in patients 
with HIV-related PAH. BREATHE-4 showed improved 
6-minute walk distance, functional class, hemodynamics, 
Doppler echocardiographic indices, and quality of life in 
a 16-week open label study of bosentan therapy.40 There 
was a 9% incidence of hepatotoxcity and there were no 
adverse interactions related to antiretroviral medications. In 
a long-term (29 ± 15 months) follow up of patients with HIV-
related PAH, Degano et al demonstrated sustained clinical 
and functional improvements. Of note, 10 of 38 patients 
undergoing repeat catheterizations had normalization of 
their pulmonary hemodynamics on bosentan.41 BREATHE-5 
evaluated bosentan therapy in 54 adult patients with PAH 
due to congenital heart disease and Eisenmenger’s syndrome. 
All subjects were NYHA Class III, and the study used a 
randomized double-blinded placebo-controlled approach 
over 16 weeks.42 Bosentan therapy improved hemodynamics 
and exercise capacity in this clinical sub-group as well.
In non-WHO Group 1 pulmonary hypertension, bosentan 
has also shown to improve functional capacity and symptoms 
in 3 prospective studies enrolling patients with pulmonary 
hypertension secondary to inoperable thromboembolic 
disease.43–45
Contrary to its beneﬁ  cial effects in PAH of WHO Group 1 
and thromboembolic disease, bosentan seems to lack efﬁ  cacy 
in pulmonary hypertension secondary to left ventricular 
failure. In a recent double-blind, randomized study 
evaluating non-invasive (echocardiographic) parameters 
of hemodynamics in patients with pulmonary hypertension 
secondary to left ventricular dysfunction, bosentan did not 
improve any endpoint and was associated with more frequent 
adverse effects.46 Similarly, bosentan was not beneﬁ  cial in 
patients with severe COPD.47
These studies emphasize the importance of establishing 
the correct diagnosis prior to institution of any therapy for 
pulmonary arterial hypertension. All patients must have 1) 
measurement of pulmonary hemodynamics via right heart 
catheterization, 2) differentiation between WHO Group 1 
and non-Group 1 forms of pulmonary hypertension, and 3) 
correct utilization of pharmacologic therapies, as different 
treatments need to be applied for different forms of pulmo-
nary hypertension.
Bosentan in combination 
therapy for PAH
PAH patient quality of life and survival remains poor despite 
the tremendous medical advances with monotherapy. The 
desire to further improve quantity and quality of life has 
led to the study of combination therapy. Bosentan has been 
used in combination with other several classes of PAH 
therapies, speciﬁ  cally prostacyclin analogues and PDE5 
inhibitors.
Bosentan and prostacyclin 
analogues
There have been 5 clinical trials investigating the efﬁ  cacy and 
safety of combining bosentan and prostanoids. The ﬁ  rst of 
these was open-label, and examined the addition of bosentan 
to either inhaled iloprost or oral beraprost (maximum toler-
ated dose) in 20 PAH patients.48 The combined therapy was 
well tolerated and there was signiﬁ  cant improvement in the 
distance walked in 6 minutes, as well as in parameters of 
exercise testing (maximal oxygen consumption, anaerobic 
threshold, oxygen pulse, ventilatory efﬁ  cacy and peak sys-
tolic blood pressure during exercise).
The ﬁ  rst placebo-control trial of add-on therapy was the 
16-week BREATHE-2 study. Thirty-three PAH patients 
(IPAH or connective tissue disease-related PAH) already 
receiving intravenous epoprostenol, had either bosentan or 
placebo added.49 At 16 weeks there was a trend toward hemo-
dynamic improvement, but no signiﬁ  cant change in NYHA 
Class or exercise capacity. In the bosentan arm of the study, 
leg edema was more frequent (27% vs 9% with placebo), but 
otherwise there was no difference in side effect proﬁ  le. In 
addition, the three deaths occurred in the combination arm. 
This study, however, was not powered to detect differences 
in efﬁ  cacy, or survival.Drug Design, Development and Therapy 2009:3 116
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The multicenter STEP trial added iloprost or placebo to 
67 NYHA Class III or IV PAH patients stably maintained on 
bosentan.50 The primary endpoint, postinhalation 6-minute 
walk distance improved by 26 meters (placebo-adjusted, 
p = 0.051) at week 12. NYHA Class, time to clinical 
worsening, and post inhalation hemodynamics also improved 
signiﬁ  cantly in patients receiving Iloprost. The combination 
appeared to be safe and well tolerated. A second trial, COMBI, 
enrolled stable idiopathic PAH patients on bosentan, random-
izing them to iloprost or placebo as a second agent.51 With the 
assumption that iloprost would improve the 6-minute walk 
distance (the primary end point) to the magnitude it improved 
as monotherapy, the study aimed at enrolling 72 patients, but 
was terminated because at the interim analysis of 40 patients 
the improvement was not signiﬁ  cant enough to continue the 
trial. Interestingly, as in the STEP trial, the three patients who 
showed signiﬁ  cant deterioration in all objective outcomes 
were in the combination arm.
Lastly, in an open-label trial, bosentan addition was stud-
ied in 16 PAH patients stable on either inhaled or intravenous 
iloprost, or oral beraprost.31 The combination improved the 
average 6-minute walk distance signiﬁ  cantly, as well as 
echocardiographic indices of right ventricular function. Nine 
patients had an improvement in NYHA Class and effects 
were sustained at 6 months and longer.
Bosentan and PDE5 inhibitors
The combination of bosentan and PDE5 inhibitors is 
theoretically appealing due to their ease of administration 
(oral) and favorable side effect profiles when used 
individually. Unfortunately, due to pharmacodynamic 
interactions (see Drug interactions), study of this has been 
largely avoided. The EARLY trial38 included 29 patients in 
the bosentan arm who were taking sildenaﬁ  l. In post hoc 
analysis, the addition of bosentan was accompanied by a 20% 
improvement in pulmonary vascular resistance and delayed 
time to clinical worsening. No signiﬁ  cant improvement in 
6-minute walk distance was found. Thus, despite the potential 
for altered drug levels, this preliminary evidence suggests 
that further study of bosentan-sildenaﬁ  l combination therapy 
may be indicated.
Transitioning from other PAH 
therapies to bosentan
Transitioning patients onto oral therapy from parental forms 
of therapy is an attractive goal for our patients with PAH. 
The ﬁ  rst study to evaluate this took 4 patients with normal 
hemodynamics on epoprostenol and transitioned them 
successfully to oral bosentan and they remained stable.52 
A subsequent study evaluated 3 children who had normal 
hemodynamics on epoprostenol and showed that these 
children after having been switched to bosentan remained 
stable for a full 1-year study period.53 However, subsequent 
studies that evaluated patients on parental prostanoids 
that did not normalize their pulmonary hemodynamics, 
only three-quarters transitioned successfully to bosentan 
and of those that transitioned more than 60% on bosentan 
therapy alone deteriorated within 3 to 16 months after 
the prostanoids were stopped.54,55 Therefore the current 
recommendation is that transitioning from prostaglandins 
to bosentan only be considered in patients who have 
normalized their pulmonary hemodynamics and who are 
under close observation.
At the bedside: clinical 
application in practice
There is arduous debate among PAH specialists regarding 
which therapy is most appropriate for which PAH patient. 
Preliminary results from the REVEAL registry, presented at 
the American College of Chest Physicians meeting in October 
2007, give us a glimpse of current clinical practice.56 Among 
the ﬁ  rst 1226 PAH patients enrolled, only 47% were being 
treated with monotherapy (bosentan 13%; sildenaﬁ  l 13%; 
epoprostenol iv 8%; sitaxsentan 2%, and calcium channel 
blockers 4%). 36% received 2-drug combination therapy 
(epoprostenol iv + sildenaﬁ  l 8%; bosentan + sildenaﬁ  l 8%; 
bosentan + epoprostenol 3%; bosentan + inhaled iloprost 
3%; and sildenaﬁ  l + inhaled iloprost 2%), and 9% received 
3 or more PAH-speciﬁ  c medications. Therefore, in the 
absence of rigorous evidence supporting multi-drug therapy, 
a diverse array of combination strategies has emerged into 
clinical practice.
In our experience, the selection of therapy must take 
into consideration an individual’s disease severity, rapidity 
of progression and signs of poor prognosis. For patients in 
NYHA Classes II and III, monotherapy with bosentan is 
often an appropriate ﬁ  rst step, assuming that the patient is 
not at increased risk for adverse effects (see Safety and toler-
ability). We agree that, despite its approval status for NYHA 
Class III and IV patients, the use of bosentan monotherapy 
for NYHA Class IV patients is not advisable, because the 
onset of improvement may take up to 6 weeks (in the ﬁ  rst 
4 weeks patients will be on the low dose of 62.5 mg twice 
a day).57 Once patients are on oral therapy, frequent (every 
1 to 3 months) monitoring of symptoms and documentation 
of NYHA classification is indicated. Demonstration of Drug Design, Development and Therapy 2009:3 117
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clinical worsening or adverse effects obviously necessitates 
immediate re-evaluation of therapeutic approach.
Conclusions, optimizing selection 
and use in therapy
The interaction between ET-1 and its receptors play a central 
role in the maintenance of pulmonary vascular homeostasis. 
Dysregulated endothelin biology is characteristic of the 
remodeled pulmonary arterioles that underlie PAH. Since their 
original description in the 1990s, ERAs such as bosentan, and 
more recently sitaxsentan and ambrisentan, have contributed to 
improved function and quality of life for patients with PAH.
Bosentan is approved for use as initial therapy for patients 
with NYHA Class II–IV PAH, although current expert opinion 
does not recommend its use as monotherapy for NYHA Class 
IV patients. The recommended dose for bosentan in adults is 
62.5 mg twice daily for 4 weeks and then increased to 125 mg 
twice daily with long-term monthly monitoring of liver function 
tests. In PAH patients taking additional therapies with potential 
drug-drug interactions, especially warfarin, PDE5 inhibitors 
and oral contraceptives, consideration of dose modiﬁ  cations 
(or avoidance of interacting medications) must be made.
Many questions about ERA therapy remain unanswered 
and deserve further study; these include exploration of the 
pharmacogenomics of these medications, determination 
of long-term response to therapy, improved insight into 
the importance of receptor selectivity, and experience 
with effective combination therapy. Despite the ongoing 
unanswered questions, the rapid translation of basic science 
into applicable and efﬁ  cacious therapies – as demonstrated 
with bosentan – for patients with PAH has had a tremendous 
impact for caring for these patients.
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